Keros Therapeutics (NASDAQ:KROS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a research report report published on Monday.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. Leerink Partners dropped their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $11.12 on Monday. The company has a market cap of $220.51 million, a price-to-earnings ratio of -3.01 and a beta of 0.99. The stock’s 50-day moving average is $10.76 and its two-hundred day moving average is $11.66. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities research analysts anticipate that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,768 shares of company stock worth $144,979. Corporate insiders own 12.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of large investors have recently made changes to their positions in KROS. California State Teachers Retirement System grew its stake in Keros Therapeutics by 72.6% during the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after buying an additional 1,148 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Keros Therapeutics by 29.5% in the second quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock valued at $761,000 after buying an additional 15,940 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $15,091,483,000. Empowered Funds LLC acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $1,521,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Keros Therapeutics during the second quarter worth approximately $538,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.